Dalbavancin — Membership Pricing
Dalbavancin is not confirmed for no-additional-cost pricing. Membership pricing may be available; confirm the price with the dispensing pharmacy.
Dalbavancin Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Membership pricing may be available |
| Typical Retail | $197.00 |
Membership pricing may be available; confirm the price with the dispensing pharmacy.
About Dalbavancin
Dalbavancin is a prescription medication. Ask your doctor if Dalbavancin is right for you.
How to Check Dalbavancin Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Dalbavancin at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Infections
What Dalbavancin is approved for (FDA label)
Dalbavancin for injection is a lipoglycopeptide antibacterial indicated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms. (1.1) To reduce the development of drug-resistant bacteria and maintain the effectiveness of dalbavancin for injection and other antibacterial drugs, dalbavancin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (1.2) 1.1 Acute Bacterial Skin and Skin Structure Infections Dalbavancin for injection is indicated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (including S. anginosus, S. intermedius, S. constellatus ) and Enterococcus faecalis (vancomycin susceptible isolates). 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of dalbavancin for injection and other antibacterial agents, dalbavancin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
Source: Read the full FDA label on DailyMed. Label effective date: July 28, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Dalbavancin (FDA label)
Dalbavancin for injection is supplied as a white/off-white to pale yellow lyophilized sterile powder for reconstitution in a single-dose clear glass vials containing dalbavancin hydrochloride equivalent to 500 mg of dalbavancin. For injection: 500 mg of lyophilized powder in a vial for reconstitution (3)
Source: FDA prescribing information (DailyMed). Set ID: f4c0bd0f-03c2-4ce5-bcc2-b58f21ce75c1. SPL document ID: ed056e1e-9906-4daf-9895-a3cbcc017b09. Label effective date: July 28, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Dalbavancin (FDA label)
The following clinically significant adverse reactions are also discussed elsewhere in the labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Infusion Related Reactions [see Warnings and Precautions (5.2)] Hepatic Effects [see Warnings and Precautions (5.3)] Clostridioides difficile -associated Diarrhea [see Warnings and Precautions (5.4)] The most common adverse reactions occurring in >4% of adult patients treated with dalbavancin for injection were nausea, headache, and diarrhea.
Source: FDA prescribing information (DailyMed). Set ID: f4c0bd0f-03c2-4ce5-bcc2-b58f21ce75c1. SPL document ID: ed056e1e-9906-4daf-9895-a3cbcc017b09. Label effective date: July 28, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Dalbavancin (FDA label)
Dalbavancin for injection is contraindicated in patients with known hypersensitivity to dalbavancin. Known hypersensitivity to dalbavancin (4)
Source: FDA prescribing information (DailyMed). Set ID: f4c0bd0f-03c2-4ce5-bcc2-b58f21ce75c1. SPL document ID: ed056e1e-9906-4daf-9895-a3cbcc017b09. Label effective date: July 28, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Dalbavancin (FDA label)
Serious hypersensitivity (anaphylactic) and skin reactions have been reported in patients treated with dalbavancin for injection. If an allergic reaction occurs, discontinue treatment with dalbavancin for injection and institute appropriate therapy for the allergic reaction. Carefully monitor patients with known hypersensitivity to glycopeptides. (5.1) Rapid intravenous infusion of dalbavancin for injection can cause flushing of the upper body, urticaria, pruritus, rash, and/or back pain. Stopping or slowing the infusion may result in cessation of these reactions. (5.2) Alanine Aminotransferase (ALT) elevations with dalbavancin for injection treatment were reported in clinical trials. (5.3, 6.1) Clostridioides difficile -associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including dalbavancin for injection. Evaluate if diarrhea occurs. (5.4) 5.1 Hypersensitivity Reactions Serious hypersensitivity (anaphylactic) and skin reactions have been reported in patients treated with dalbavancin for injection.
Source: FDA prescribing information (DailyMed). Set ID: f4c0bd0f-03c2-4ce5-bcc2-b58f21ce75c1. SPL document ID: ed056e1e-9906-4daf-9895-a3cbcc017b09. Label effective date: July 28, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Dalbavancin (FDA label)
7.1 Drug-Laboratory Test Interactions Drug-laboratory test interactions have not been reported. Dalbavancin for injection at therapeutic concentrations does not artificially prolong prothrombin time (PT) or activated partial thromboplastin time (aPTT). 7.2 Drug-Drug Interactions No clinical drug-drug interaction studies have been conducted with dalbavancin for injection. There is minimal potential for drug-drug interactions between dalbavancin for injection and cytochrome P450 (CYP450) substrates, inhibitors, or inducers [see Clinical Pharmacology (12.3)].
Source: FDA prescribing information (DailyMed). Set ID: f4c0bd0f-03c2-4ce5-bcc2-b58f21ce75c1. SPL document ID: ed056e1e-9906-4daf-9895-a3cbcc017b09. Label effective date: July 28, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.